Healthcare Innovation Partners

Bridging Innovation and Access in Healthcare

We partner with biotechnology, medical device, and diagnostic companies primarily in the North America to improve access and delivery.

Learn More

Social Impact

Investing with Purpose

Access & Delivery

Transforming how healthcare reaches patients

10% GP Carry Donated

Supporting nonprofit cancer & cardiac research

Tangible Impact

Investing where measurable healthcare outcomes can be seen

Medical Team

People

Our Team

Our team is composed of clinicians, researchers, big pharma executives, and venture capitalists who have successfully built and invested in dozens of healthcare companies.

Investment Approach

Stage & Approach

Our Investment Approach

We primarily invest in Seed through Series B, targeting high-potential, growth-stage ventures with proven traction and strong market validation. Our disciplined approach ensures that capital is deployed where it can accelerate meaningful innovation and drive measurable impact in healthcare.

Areas of Investment

Strategic Sectors

We invest in companies that will transform the way healthcare is accessed or delivered. These opportunities can include pharmaceuticals, diagnostics, and devices. Our primary focus is on Cancer and Cardiac innovation.

Medical Team

Advancing next-generation cancer treatments and diagnostics

Cancer & Therapeutics Focus

Potential areas of investment include innovative cancer therapeutics such as antibody-drug conjugates (ADCs), cancer vaccines using mRNA technology, advanced cell and targeted therapies. We also focus on emerging radioligand treatments and next-generation diagnostic and monitoring technologies, including advanced imaging and liquid biopsy platforms that enable earlier detection and more precise treatment strategies.

Investment Approach

Transforming cardiac diagnostics and treatment

Cardiac Innovation

Potential areas of investment include cardiac diagnostic tools or minimally invasive delivery techniques that often have shorter regulatory timelines than new drugs, as well as advanced therapies like gene and stem cell therapies aimed at conditions such as heart failure, arrhythmias and other cardiac diseases.

Medical Team

Selective opportunities across high-impact disease areas

Additional Opportunistic Investments

Other opportunistic investments may include opportunities in areas such as neurology, metabolic diseases, or chronic disease platforms. These investments focus on innovative solutions targeting conditions including neurodegenerative disorders and other complex diseases where new technologies can significantly improve patient outcomes.